Abstract
Imipenem-cilastatin (imipenem 1 to 4 g/day) was administered to patients with severe infections accompanying granulocytopenia in hematological malignancies. Monotherapy with imipenem-cilastatin was effective in 62.1% of the patients, and also effective even they were severely neutropenic. When imipenem-cilastatin was administered as the first-choice therapy, the efficacy was much better, at 73.3%. Both Gram-positive and Gram-negative infections were curable by the monotherapy with imipenem-cilastatin.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Agranulocytosis / etiology
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Infections / drug therapy*
-
Bacterial Infections / etiology
-
Cilastatin / therapeutic use*
-
Cilastatin, Imipenem Drug Combination
-
Drug Combinations
-
Female
-
Humans
-
Imipenem / therapeutic use*
-
Leukemia / complications*
-
Lymphoma / complications*
-
Male
-
Neutropenia / etiology
Substances
-
Anti-Bacterial Agents
-
Drug Combinations
-
Cilastatin
-
Imipenem
-
Cilastatin, Imipenem Drug Combination